Marksans Pharma
Marksans Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Marksans Pharma
Start SIPMarksans Pharma Investment Rating
-
Master Rating:
-
Marksans Pharma has an operating revenue of Rs. 1,852.14 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 18% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 33% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 153 | 173 | 170 | 159 | 176 |
| Operating Expenses Qtr Cr | 130 | 149 | 136 | 148 | 149 |
| Operating Profit Qtr Cr | 23 | 24 | 34 | 12 | 27 |
| Depreciation Qtr Cr | 4 | 4 | 5 | 5 | 5 |
| Interest Qtr Cr | 1 | 1 | 1 | 1 | 1 |
| Tax Qtr Cr | 5 | 9 | 9 | 6 | 7 |
| Net Profit Qtr Cr | 18 | 26 | 40 | 19 | 21 |
Marksans Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹77.78
- 50 Day
- ₹75.31
- 100 Day
- ₹71.13
- 200 Day
- ₹65.58
- 20 Day
- ₹76.56
- 50 Day
- ₹75.8
- 100 Day
- ₹70.85
- 200 Day
- ₹62.17
Marksans Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹86.04 |
| Second Resistance | ₹87.87 |
| Third Resistance | ₹89.24 |
| RSI | 62.78 |
| MFI | 79.49 |
| MACD Single Line | 0.52 |
| MACD | 1.57 |
| Support | |
|---|---|
| First Resistance | ₹82.84 |
| Second Resistance | ₹81.47 |
| Third Resistance | ₹79.64 |
Marksans Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,630,204 | 105,681,597 | 40.18 |
| Week | 8,537,614 | 255,786,909 | 29.96 |
| 1 Month | 3,021,633 | 112,102,567 | 37.1 |
| 6 Month | 2,704,129 | 104,298,254 | 38.57 |
Marksans Pharma Result Highlights
Marksans Pharma Synopsis
NSE-Medical-Diversified
Marksans Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 655.20 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2023. Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364.| Market Cap | 3,750 |
| Sales | 655 |
| Shares in Float | 25.38 |
| No of funds | 71 |
| Yield | 0.6 |
| Book Value | 3.37 |
| U/D Vol ratio | 2 |
| LTDebt / Equity | |
| Alpha | 0.24 |
| Beta | 0.64 |
Marksans Pharma
| Owner Name | Mar-23 | Jan-23 | Dec-22 | Sep-22 |
|---|---|---|---|---|
| Promoters | 43.85% | 43.8% | 49% | 48.6% |
| Mutual Funds | 0.86% | 0.86% | 0.96% | 0.95% |
| Foreign Portfolio Investors | 4.23% | 3.94% | 4.23% | 4.06% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 34.42% | 35.19% | 39.69% | 39.76% |
| Others | 16.64% | 16.21% | 6.12% | 6.63% |
Marksans Pharma Management
| Name | Designation |
|---|---|
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mr. Seetharama R Buddharaju | Independent Director |
| Dr.(Mrs.) Meena Rani Surana | Independent Director |
Marksans Pharma Forecast
Price Estimates
Marksans Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-30 | Audited Results & Final Dividend | |
| 2023-02-13 | Quarterly Results | |
| 2023-01-20 | Others | Re.0.00 alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis. |
| 2022-11-14 | Quarterly Results | |
| 2022-08-13 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-06-07 | FINAL | Rs.0.50 per share(50%)Final Dividend |
Marksans Pharma FAQs
What is Share Price of Marksans Pharma ?
Marksans Pharma share price is ₹82 As on 05 June, 2023 | 01:27
What is the Market Cap of Marksans Pharma ?
The Market Cap of Marksans Pharma is ₹3749.9 Cr As on 05 June, 2023 | 01:27
What is the P/E ratio of Marksans Pharma ?
The P/E ratio of Marksans Pharma is 14.1 As on 05 June, 2023 | 01:27
What is the PB ratio of Marksans Pharma ?
The PB ratio of Marksans Pharma is 2.1 As on 05 June, 2023 | 01:27